{"id":7396,"date":"2020-06-08T15:40:02","date_gmt":"2020-06-08T22:40:02","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7396"},"modified":"2021-03-24T15:40:47","modified_gmt":"2021-03-24T22:40:47","slug":"interleukin-1-blockade-with-high-dose-anakinra-in-patients-with-covid-19-acute-respiratory-distress-syndrome-and-hyperinflammation-a-retrospective-cohort-study","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/08\/interleukin-1-blockade-with-high-dose-anakinra-in-patients-with-covid-19-acute-respiratory-distress-syndrome-and-hyperinflammation-a-retrospective-cohort-study\/","title":{"rendered":"Interleukin-1 Blockade with High-Dose Anakinra in Patients with COVID-19, Acute Respiratory Distress Syndrome, and Hyperinflammation:\u00a0A Retrospective\u00a0Cohort Study"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"36\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Cavalli et al. observed that patients (n=29) who received a high-dose of intravenous anakinra (an interleukin (IL)-1 receptor blocker) had a higher probability of survival at 21 days among a cohort of patients with COVID-19 who had moderate-to-severe ARDS and hyperinflammation and who were managed with non-invasive ventilation outside of the ICU. Treated patients were compared to patients who received standard-of-care at the time (hydroxychloroquine and lopinavir\/ritonavir).\u00a0Probability\u00a0of bacteremia was nearly equivalent in the two groups. Low-dose subcutaneous anakinra had no appreciable effects on clinical status or biomarkers.\u00a0\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Cavalli et al. (June 2020). Interleukin-1 Blockade with High-Dose Anakinra in Patients with COVID-19, Acute Respiratory Distress Syndrome, and Hyperinflammation:\u00a0A Retrospective\u00a0Cohort Study.\u00a0The Lancet\u00a0Rheumatology.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S2665-9913(20)30127-2\"><i><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/S2665-9913(20)30127-2<\/span><\/i><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cavalli et al. observed that patients (n=29) who received a high-dose of intravenous anakinra (an interleukin (IL)-1 receptor blocker) had a higher probability of survival at 21 days among a cohort of patients with COVID-19 who had moderate-to-severe ARDS and hyperinflammation and who were managed with non-invasive ventilation outside of the ICU. Treated patients were&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/08\/interleukin-1-blockade-with-high-dose-anakinra-in-patients-with-covid-19-acute-respiratory-distress-syndrome-and-hyperinflammation-a-retrospective-cohort-study\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7396","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7396"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7396\/revisions"}],"predecessor-version":[{"id":7397,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7396\/revisions\/7397"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7396"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}